News | September 26, 2024
Pfizer withdraws all lots of sickle cell disease treatment voxelotor
Pfizer's decision is based on the totality of clinical data
Pfizer's decision is based on the totality of clinical data
She reiterated the nation's commitment to eliminating TB as a public health problem by 2030 and ensuring a healthier future for all
The objectives of the campaign are to raise awareness about glaucoma, its risk factors, and the importance of regular eye check-up
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
This license will enable Abbott to enhance access to this novel therapy to more patients across India
ACOIN has recognized Dr. Budhrani's exceptional work in promoting community and clinical ophthalmology
This approval is backed by a decade of proven safety and efficacy data of Ocrevus® IV, with over 350,000 people treated globally
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous
The acquisition is based on an enterprise value of Rs. 1,660 crore
Subscribe To Our Newsletter & Stay Updated
